Efficacy & safety of brolucizumab 6.0 mg versus 3.6 mg in diabetic macular edema

Efficacy & safety of brolucizumab 6.0 mg versus 3.6 mg in diabetic macular edema

Abstract Background Management of Diabetic Macular edema (DME) requires repeated injections. Therefore newer Anti-VEGFs like Brolucizumab with longer durability have been introduced. We compared two different dosages of Brolucizumab, 6.0 mg and 3.6 mg, for their safety & efficacy in treatment of...

Full description

Saved in:
Bibliographic Details
Main Authors: Sanjay Kumar Mishra, Pradeep Kumar, Amrita Joshi, Aman Saraf, Abhijeet Awasthi, Supriya Dhar, Khaleel M, Atul Kumar, Vipin Rana, Ravi D
Format: Article
Language:English
Published: BMC 2025-01-01
Series:International Journal of Retina and Vitreous
Subjects:
Diabetic macular edema
DME
Brolucizumab
VEGF
India
Online Access:https://doi.org/10.1186/s40942-025-00628-x
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s40942-025-00628-x

Similar Items